BusinessCellular Biomedicine Group Announces Chairman of the Board of Directors, and Appointment of Chief Executive OfficerBy Nasdaq OMXJan 28, 2016, 11:00 AM UTC
BusinessCellular Biomedicine Group Announces Positive 48-Week Data From Phase IIb Clinical Trial for Knee Osteoarthritis Stem Cell ReJoin® TherapyBy Nasdaq OMXJan 13, 2016, 1:00 PM UTC
BusinessCellular Biomedicine Group Selected to Present at Biotech Showcase™ 2016By Nasdaq OMXJan 8, 2016, 2:00 PM UTC
BusinessCellular Biomedicine Group Launches Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee OsteoarthritisBy Nasdaq OMXJan 6, 2016, 2:04 PM UTC
